Sustained administration of the antidepressant venlafaxine in rats: pharmacokinetic and pharmacodynamic findings.
Rats were administered venlafaxine (10 mg/kg per day) for 14 days by using subcutaneously implanted osmotic minipumps. The present study assessed the distribution of VEN in different compartments, whether the VEN concentration in the compartments correlated, the effect of VEN on dialysate monoamine levels and on the spontaneous open-field behavior, and possible relations between the pharmacokinetic and pharmacodynamic parameters. The venlafaxine level in serum after sustained treatment was about 25% of the concentration in brain parenchyma and much higher than in brain dialysate. There was a clear correlation between venlafaxine concentrations in blood and brain compartments. The sustained venlafaxine challenge resulted in higher neocortical concentration of serotonin and noradrenaline, lower 5-hydroxyindole-3-acetic acid levels and increased locomotor activity in the central part of the test arena as compared to controls. No correlations were found between the venlafaxine concentration and brain monoamine parameters or the open-field behaviors. We conclude that, although species differences in pharmacokinetic properties for venlafaxine between rat and man exist, the pharmacokinetic correlations found after sustained treatment add information to the in vivo nature of the drug. Also, more studies like the present need to be performed to find the pharmacokinetic/pharmacodynamic interrelations for drugs like VEN.
Wikell
C
C
Department of Clinical Pharmacology, Lund University, Sweden.
Hjorth
S
S
Apelqvist
G
G
Kullingsjö
J
J
Lundmark
J
J
Bergqvist
P B
PB
Bengtsson
F
F
D000818:Animals; D018687:Antidepressive Agents, Second-Generation / Q000493:pharmacokinetics / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects*; D015306:Biogenic Monoamines / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D003511:Cyclohexanols / Q000493:pharmacokinetics / Q000494:pharmacology*; D008297:Male; D017551:Microdialysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D014018:Tissue Distribution; D000069470:Venlafaxine Hydrochloride
D018687:Antidepressive Agents, Second-Generation; D015306:Biogenic Monoamines; D003511:Cyclohexanols; D000069470:Venlafaxine Hydrochloride